A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Start-Ups with Predictive ADME/Tox Technologies, features Medisyn Technologies Inc., PhysioGenix Inc., Qualyst Inc. and QuantumBio Inc. Plus these Start-Ups across Health Care: Arthrosurface Inc., CardioKine Inc. and Emphasys Medical Inc.

Ask a head of R&D for a pharma or biotech to name the area where the need for new and better tools is greatest, and likely as not the answer will be predictive modeling of a drug's ADME/Tox profile. There's an abundance of sweet spots across the preclinical landscape for companies with better models and predictive tools.

Imagine having the capability to design multiple qualified drug leads in weeks using in silico methodologies. That's what Medisyn Technologies says it is doing for itself and partners by correlating molecular topography with activity and other drug properties.